HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on TScan Therapeutics (NASDAQ:TCRX) and maintained a $15 price target.
March 07, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on TScan Therapeutics with a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst could lead to increased investor confidence in TScan Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100